6D·

$BNTX (-3,32 %) Jeffries has raised the price targets for BioNTech today 😀


The share price has suffered recently, but with a weekly balance of +37% and a monthly balance of +47%, it is heading in the right direction again🚀


The target price adjustment reflects the potential that BioNTech's ongoing research and development activities could have for the company's future prospects.


BioNTech's strategy is to prioritize chemotherapy combinations before exploring antibody-drug conjugate (ADC) combinations. To this end, the company has initiated global Phase 2 trials of BNT327 in combination with chemotherapy for breast cancer (BC) and small cell lung cancer (SCLC). In addition, BioNTech plans to complete a first-line study in lung cancer.


Biontech is aiming for first market approval for a cancer drug in 2026, after which annual market approvals in oncology are planned.


Current stock: 131 units

13
18 Comentarios

Imagen de perfil
I've been in here since 2020, at times with over 400% and then back to the starting point 😅. I missed the exit back then and since then I've been keeping my fingers crossed that BioNTech manages to beat cancer. A good share price would then be almost secondary. But so far it remains more of a dream ;)
11
Ver todas las 10 respuestas adicionales
Imagen de perfil
Hallelujah that's a thing
1
Ver todas las 4 respuestas adicionales
Imagen de perfil
Seems like it's going to continue like this on Monday. Great data from the ESMO on BNT327. Nice to see the position in positive territory again, it's been a really long time chewing soap.
1
Mostrar respuesta

Únase a la conversación